1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-9. Epub 2002/03/27.
2. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010;16(11):888-900. Epub 2010/11/09.
3. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010;56(13):1001-12. Epub 2010/09/18.
4. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42. Epub 2008/09/27.
5. Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol. 2007;82(12 Suppl):1128-31. Epub 2007/10/30.
6. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386-95. Epub 2005/12/13.
7. N. Gattermann ER. Iron overload in MDS – pathophysiology, diagnosis and complications2005. Available from: http://ganymedes.lib.unideb.hu:8080/udpeer/bitstream/2437.2/13607/1/PEE….
8. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008;22 Suppl 2:S14-21. Epub 2008/12/17.
9. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J. 2003;24(1):113-9. Epub 2003/02/01.
10. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol. 2009;25(4):213-8. Epub 2009/04/03.
11. Kwiatkowski JL. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med. 2011;2:135-49. Epub 2012/01/31.
12. Nemeth E. Hepcidin in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:31-5. Epub 2010/08/18.
13. Anderson G, McLaren G. Iron Physiology and Pathophysiology in Humans: Humana Press; 2012.
14. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51(2):209-21. Epub 1971/08/01.
15. Fragasso A, Ciancio A, Mannarella C, Gaudiano C, Scarciolla O, Ottonello C, et al. Myocardial iron overload assessed by magnetic resonance imaging (MRI)T2* in multi-transfused patients with thalassemia and acquired anemias. Eur J Intern Med. 2011;22(1):62-5. Epub 2011/01/18.
16. Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. Br J Haematol. 2011;154(4):521-4. Epub 2011/06/22.
17. Leung AW, Chu WC, Lam WW, Lee V, Li CK. Magnetic resonance imaging assessment of cardiac and liver iron load in transfusion dependent patients. Pediatr Blood Cancer. 2009;53(6):1054-9. Epub 2009/07/21.
18. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol. 1994;87(1):171-84. Epub 1994/05/01.
19. Mavrogeni SI, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, Karavolias G, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. European Journal of Haematology. 2005;75(3):241-7.
20. Barrera Portillo MC, Uranga Uranga M, Sanchez Gonzalez J, Alustiza Echeverria JM, Gervas Wells C, Guisasola Iniguez A. Liver and heart T2* measurement in secondary haemochromatosis. Radiologia. 2012. Epub 2012/01/17. Medicion del T2* hepatico y cardiaco en la hemocromatosis secundaria.
21. Suarez WA, Snyder SA, Berman BB, Brittenham GM, Patel CR. Preclinical cardiac dysfunction in transfusion-dependent children and young adults detected with low-dose dobutamine stress echocardiography. J Am Soc Echocardiogr. 1998;11(10):948-56. Epub 1998/11/06.
22. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18(5):616-20. Epub 2003/10/28.
23. Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev. 2011;25(1):17-31. Epub 2010/10/30.
24. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93(9):1385-8. Epub 2008/07/08.
25. Bennett JM. Myelodysplastic Syndromes: pathobiology and clinical management. New York: Marcel Dekker; 2002.
26. Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol. 2007;82(11):1013-6. Epub 2007/07/27.
27. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-603. Epub 2005/09/28.
28. Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. Drugs. 2011;71(2):155-77. Epub 2011/02/01.
29. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114(26):5251-5. Epub 2009/08/28.
30. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78(6):487-94. Epub 2007/03/30.
31. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138(5):587-93. Epub 2007/07/06.
32. Mavrogeni S. Comparison of myocardial and hepatic iron loading, assessed by MRI T2*, in patients with myelodysplastic syndromes, thalassaemia major and controls. Blood Transfus. 2012;10(2):237-40. Epub 2012/01/17.
33. L. GS, N. M-P, N. W. Prevalence of cardiac disease among a US medicare population with myelodysplastic syndromes. LEUKEMIA RESEARCH. 2007;31:S103-S.
34. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34(7):864-70. Epub 2010/02/05.
35. Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, et al. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95(2):149-59. Epub 2011/12/24.
36. Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the current literature. Br J Haematol. 2012. Epub 2012/04/26.
37. Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008;48(9):1971-80. Epub 2008/06/03.
38. Blink, Evert. Basis MRI principes. 2004; Available from: http://www.angelfire.com/planet/mri/MRIdetechniek.pdf.
39. Faulkner W. Basic Principles of MRI. 1996.
40. MRI physics. 2011; Available from: http://www.iomonitoring.pro/mrphysics.htm.
41. Ghugre NR, Coates TD, Nelson MD, Wood JC. Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med. 2005;54(5):1185-93. Epub 2005/10/11.
42. Wood JC, Ghugre N. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin. 2008;32(1-2):85-96. Epub 2008/02/16.
43. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. Epub 2009/04/10.